From - A Hematology Oncology Wiki
Jump to navigation Jump to search

Note: this page contains information on multiple formulations of cyclosporine.

General information

Class/mechanism: Cyclic polypeptide immunosuppressive agent that reversibly and preferentially inhibits T-lymphocytes, especially the T-helper cell. Exact mechanism unknown. Suppresses humoral immunity and cell-mediated immune reactions, including graft vs. host disease, allograft rejection, delayed hypersensitivity, experimental allergic encephalomyelitis, and Freund’s adjuvant arthritis. The Neoral formulation forms a microemulsion when present in an aqueous environment.
Please choose from the products below to find specific drug/manufacturer information:

Route: IV, PO
Extravasation: no information

For conciseness and simplicity, currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Diseases for which it is used

Patient drug information

History of changes in PMDA indication

  • 2017-08-25: Revised indication and a new dosage for the treatment of aplastic anemia which is not severe.

Also known as

  • Generic names: ciclosporin, CsA, CyA, cyclosporin, cyclosporin A
  • Brand names: Sandimmune, Gengraf, Neoral